Genetic predictors of cardiovascular mortality during intensive glycemic control in type 2 diabetes: Findings from the ACCORD clinical trial

Diabetes Care

Volumn 39, Issue 11, 2016, Pages 1915-1924

  Shah, Hetal S ^a,b   Gao, He ^a,b   Morieri, Mario Luca ^a,b   Skupien, Jan ^a,b,c   Marvel, Skylar ^d   Paré, Guillaume ^e   Mannino, Gaia C ^a,b   Buranasupkajorn, Patinut ^a,b,f   Mendonca, Christine ^a   Hastings, Timothy ^a   Marcovina, Santica M ^g   Sigal, Ronald J ^h   Gerstein, Hertzel C ^e   Wagner, Michael J ⁱ   Motsinger Reif, Alison A ^d   Buse, John B ^j   Kraft, Peter ^k   Mychaleckyj, Josyf C ^l   Doria, Alessandro ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

^e HAMILTON HEALTH SCIENCES   (Canada)

^f CHULALONGKORN UNIVERSITY   (Thailand)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ University of North Carolina   (United States)

^j UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^k HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^l UNIVERSITY OF VIRGINIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHROMOSOME 10Q; CHROMOSOME 5Q; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; GENE LOCUS; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; SELF REPORT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84994338421     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0285     Document Type: Conference Paper

References (34)

1. Go AS, Mozaffarian D, Roger VL, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: A report from the American Heart Association. Circulation 2014;129:e28-e292
2. American Diabetes Association. Cardiovascular disease and risk management. Sec. 8. In Standards of Medical Care in Diabetesd2015. Diabetes Care 2015;38(Suppl. 1):S49-S57
3. World Health Organization. Global Status Report on Non-Communicable Diseases 2014. Geneva, World Health Org. 2014 (6-6-2015)
4. Turnbull FM, Abraira C, Anderson RJ, et al.; Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes [published correction appears in Diabetologia 2009;52:2470]. Diabetologia 2009;52:2288-2298
5. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559
6. Gerstein HC, Miller ME, Genuth S, et al.; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-828
7. Calles-Escandón J, Lovato LC, Simons-Morton DG, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010;33: 721-727
8. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909
9. Miller ME, Bonds DE, Gerstein HC, et al.; ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010;340:b5444
10. Riddle MC, Ambrosius WT, Brillon DJ, et al.; Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33:983-990
11. Hempe JM, Liu S, Myers L, McCarter RJ, Buse JB, Fonseca V. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care 2015;38:1067-1074
12. Buse JB, Bigger JT, Byington RP, et al.; ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99(12A):21i-33i
13. Prudente S, Shah H, Bailetti D, et al. Genetic variant at the GLUL locus predicts all-cause mortality in patients with type 2 diabetes. Diabetes 2015;64:2658-2663
14. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328
15. Mychaleckyj JC, Farber EA, Chmielewski J, et al. Buffy coat specimens remain viable as a DNA source for highly multiplexed genome-wide genetic tests after long termstorage. J TranslMed 2011;9:91
16. Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3 (Bethesda) 2011;1:457-470
17. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 2010;26:2190-2191
18. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319: 1492-1495
19. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 2015;348:648-660
20. Krolewski AS, Laffel LM, KrolewskiM, Quinn M, Warram JH. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995;332:1251-1255
21. Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin EndocrinolMetab 2010;95:1566-1574
22. Teo AK, Oh HK, Ali RB, Li BF. The modified human DNA repair enzyme O(6)-methylguanine-DNA methyltransferase is a negative regulator of estrogen receptor-mediated transcription upon alkylation DNA damage. Mol Cell Biol 2001;21: 7105-7114
23. Shearman AM, Cupples LA, Demissie S, et al. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 2003;290:2263-2270
24. Lucas G, Lluís-Ganella C, Subirana I, et al.; CARDIoGRAM Consortium. Post-genomic update on a classical candidate gene for coronary artery disease: ESR1. Circ Cardiovasc Genet 2011; 4:647-654
25. Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012;22:1790-1797
26. Watson PA, Nesterova A, Burant CF, Klemm DJ, Reusch JE. Diabetes-related changes in cAMP response element-binding protein content enhance smoothmuscle cell proliferation andmigration. J Biol Chem 2001;276:46142-46150
27. Shahni R, Gnudi L, King A, Jones P, Malik AN. Elevated levels of renal and circulating Nop-7-associated 2 (NSA2) in rat and mouse models of diabetes, in mesangial cells in vitro and in patients with diabetic nephropathy. Diabetologia 2012;55:825-834
28. Shahni R, Czajka A, Mankoo BS, Guvenel AK, King AJ, Malik AN. Nop-7-associated 2 (NSA2), a candidate gene for diabetic nephropathy, is involved in the TGFb1 pathway. Int J Biochem Cell Biol 2013;45:626-635
29. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem 2012; 81:145-166
30. Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res 2012;22: 1775-1789
31. Beltrami C, Angelini TG, Emanueli C.Noncoding RNAs in diabetes vascular complications. J Mol Cell Cardiol 2015;89:42-50
32. Leung A, Natarajan R. Noncoding RNAs in vascular disease. Curr Opin Cardiol 2014;29: 199-206
33. Thiel S, Petersen SV, Vorup-Jensen T, et al. Interaction of C1q and mannan-binding lectin (MBL) with C1r, C1s, MBL-associated serine proteases 1 and 2, and the MBL-associated protein MAp19. J Immunol 2000;165:878-887
34. Malzahn D, Balavarca Y, Lozano JP, Bickeböller H. Tests for candidate-gene interaction for longitudinal quantitative traitsmeasured in a large cohort. BMC Proc 2009;3(Suppl. 7):S80